요로감염에 대한 Enoxacin(Flumark R)의 효과: 임상 및 항균 감수성 검토
Effect of Enoxacin(Flumark) in Urinary Tract Infection: clinical and antimicrobial susceptibility evaluation
소속 상세정보
김영균/Kim YK
이은식/이성원/정기현/이안기/Lee ES/Lee SW/Chung KH/Lee AK
KMID : 0358319870280040541
Abstract
Effect of Enoxacin (Flumark), an oral pyridone carboxylic acid, in the urinary tract infection was evaluated clinically and susceptibility of 292 strains of microorganism isolated from urine to the various antimicrobial agents was tested and compared. Thirty six patients with urinary tract infection were given with 300 to 600mg of Enoxacin daily for 7 to 14 days according to severity of urinary tract infection. The clinical symptoms and urinary findings improved in 30 patients (83.3%) and no clinical response was achieved in 6 patients (16.7%), but revealing 100% response in 9 patients of acute uncomplicated cystitis. In the antimicrobial susceptibility test, Enoxacin was much superior to aminoglycoside, especially against Pseudomonas aeruginosa. Serratia spp., Enterobacter spp. and other Pseudomonas spp.. Enoxacin is a very effective and safe antimicrobial agent in treatment of the urinary tract infection.
키워드
요로감염; 항생제; enoxacin; urinary tract infection; susceptibility
원문 및 링크아웃 정보
등재저널 정보